For the year ending 2025-12-31, AMLX has $332,645K in assets. $27,386K in debts. $226,651K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 226,651 | |||
| Marketable securities | 90,328 | |||
| Accounts receivable, net | 88 | |||
| Prepaid expenses and other current assets | 6,604 | |||
| Total current assets | 323,671 | |||
| Total property and equipment | 1,864 | |||
| Less accumulated depreciation | 1,554 | |||
| Property and equipment, net | 310 | |||
| Restricted cash equivalents | 985 | |||
| Operating lease right-of-use assets | 5,181 | |||
| Deposits and other assets | 2,498 | |||
| Total assets | 332,645 | |||
| Accounts payable | 3,519 | |||
| Accrued expenses | 17,910 | |||
| Operating lease liabilities, current portion | 1,259 | |||
| Total current liabilities | 22,688 | |||
| Operating lease liabilities, net of current portion | 4,698 | |||
| Total liabilities | 27,386 | |||
| Common stock, 0.0001 par value 300,000,000 shares authorized 109,884,502 and 68,629,738 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 11 | |||
| Additional paid-in capital | 1,056,271 | |||
| Accumulated deficit | -751,427 | |||
| Accumulated other comprehensive income (loss) | 404 | |||
| Total stockholders' equity | 305,259 | |||
| Total liabilities and stockholders' equity | 332,645 | |||
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)